document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule item summary signature right trademark copyright trade name business include follow gilead gilead science ambisome atripla biktarvy cayston complera descovy emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvadaforprep tybost vemlidy viread vosevi yescarta zydelig lexiscan register trademark astella llc macugen register trademark eyetech inc symtuza register trademark janssen sciences ireland uc tamiflu register trademark hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue forecast variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forwardlooke statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forward look statement reason include identify item annual report head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration highlight mark operational excellence transition position future growth business continue develop deliver innovative medicine help people lifethreatene illness world highlight performance include hiv achieve record sale hiv product hiv product revenue increase united states worldwide compare growth drive successful launch biktarvy continue strong uptake single tablet regimen contain tenofovir alafenamide taf treatment hiv infection truvada preexposure prophylaxis prep indication hiv prevention biktarvy oncedaily single tablet regimen contain bictegravir emtricitabine taf treatment hiv infection adult approve food drug administration fda february european commission june liver disease revenue chronic hepatitis c virus hcv product predictable want introduce lower price alternative hcv product significant disruption healthcare system business authorize launch generic version epclusa harvoni united states start january separate subsidiary asegua therapeutics llc asegua continue advance clinical trial treatment chronic hepatitis b virus hbv nonalcoholic steatohepatitis nash include complete enrollment phase clinical trial nash cell therapy immunooncology advanced pipeline cancer therapy position leader cell therapy yescarta approve european commission august treatment relapse refractory diffuse large bcell lymphoma dlbcl primary mediastinal large bcell lymphoma pmbcl line systemic therapy certify additional center united states europe provide treatment yescarta order advance accelerate research development effort cell therapy immunooncology year enter key strategic collaboration national cancer institute pfizer inc pfizer sangamo therapeutics inc sangamo gadeta bv gadeta hifibio therapeutics hifibio tango therapeutics tango agenus inc agenus inflammation continue advance pipeline novel investigational agent inflammatory disease include announce positive datum filgotinib ongoing phase clinical trial enter strategic collaboration verily life sciences llc alphabet company verily verilys immunoscape platform identify well understand immunological basis inflammatory disease year continue invest advance research development pipeline therapeutic area end research development pipeline include active clinical study phase clinical trial additionally complete collaboration partnership strategic investment reflect commitment enable access new technology drug candidate potential evolve care people lifethreatene illnesse investment research development reflect commitment expand pipeline range disease address area significant unmet medical need position longterm growth business principal product innovative medicine represent advancement offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy focus innovation allow deliver market product primary area focus hivaid liver disease hematologyoncology inflammationrespiratory disease principal product approve indication united states follow hivaids biktarvy oral formulation dose day treatment hiv infection certain patient biktarvy single tablet regimen fixeddose combination antiretroviral medication bictegravir emtricitabine taf descovy oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient descovy fixeddose combination antiretroviral medication emtricitabine taf odefsey oral formulation dose day treatment hiv infection certain patient odefsey single tablet regimen fixeddose combination antiretroviral medication emtricitabine taf rilpivirine market janssen sciences ireland uc janssen pharmaceutical companies johnson johnson janssen genvoya oral formulation dose day treatment hiv infection certain patient genvoya single tablet regimen fixeddose combination antiretroviral medicine elvitegravir cobicistat emtricitabine taf stribild oral formulation dose day treatment hiv infection certain patient stribild single tablet regimen fixeddose combination antiretroviral medication elvitegravir cobicistat tenofovir disoproxil fumarate tdf emtricitabine compleraeviplera oral formulation dose day treatment hiv infection certain patient product market united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medication tdf emtricitabine janssen rilpivirine hydrochloride atripla oral formulation indicate complete regimen treatment hiv infection certain patient atripla fixeddose combination antiretroviral medication tdf emtricitabine bristolmyers squibb companys bmss efavirenz truvada oral formulation indicate combination antiretroviral agent treatment hiv infection certain patient fix dose combination antiretroviral medication tdf emtricitabine fda approve truvada prep indication combination safe sex practice reduce risk sexually acquire hiv infection certain atrisk patient liver disease vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adult genotype previously treat nsa inhibitorcontaine regimen ii genotype previously treat sofosbuvircontaine regimen nsa inhibitor vemlidy oral formulation taf dose day treatment chronic hbv infection adult compensate liver disease epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii decompensate cirrhosis use combination ribavirin harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adult genotype cirrhosis compensate cirrhosis ii adult genotype infection decompensate cirrhosis combination ribavirin ii adult genotype liver transplant recipient cirrhosis compensate cirrhosis combination ribavirin iv certain pediatric patient genotype cirrhosis compensate cirrhosis viread oral formulation tdf dose day treatment chronic hbv infection adult certain pediatric patient hematologyoncology yescarta axicabtagene ciloleucel car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include dlbcl specify pmbcl highgrade bcell lymphoma dlbcl arise tfl zydelig idelalisib oral formulation kinase inhibitor treatment patient relapse chronic lymphocytic leukemia cll combination rituximab rituximab consider appropriate therapy comorbidities ii relapse follicular bcell non hodgkin lymphoma fl patient receive prior systemic therapy iii relapse small lymphocytic lymphoma receive prior systemic therapy letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsen ii combination tadalafil reduce risk disease progression hospitalization worsen pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment invasive fungal infection cause fungal specie adult information product revenue include revenue contribute product list fiscal year note revenue note consolidated financial statement include item annual report commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute product united states exclusively wholesale channel product sale large wholesaler mckesson corporation amerisourcebergen corporation cardinal health inc account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue sell distribute product europe country outside united states product approve commercial team thirdparty distributor corporate partner competition operate highly competitive environment face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete commercially available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect description competitor item risk factor face significant competition research development research development rd philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource internal rd opportunity external business development activity product development effort cover wide range medical condition include hivaid liver disease hematologyoncology inflammationrespiratory disease research scientist engage discovery development new molecule technology hope lead approval new medicine advance current standard care address unmet medical need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development product candidate treatment hivaid product candidate description product phase descovy descovy evaluate prep indication product phase gs gs nucleoside reverse transcriptase inhibitor evaluate treatment hiv infection product phase gs gs capsid inhibitor evaluate treatment hiv infection vesatolimod vesatolimod gs tlr agonist evaluate potential cure hiv infection gs gs broadly neutralize antibody evaluate potential cure hiv infection product candidate treatment liver disease product candidate description product phase selonsertib selonsertib ask inhibitor evaluate stellar trial treatment nash bridge fibrosis product phase gs gs tlr agonist evaluate treatment hbv infection cilofexor gs fxr agonist evaluate treatment nash primary biliary cirrhosis cilofexor primary sclerose cholangitis firsocostat firsocostat gs acc inhibitor evaluate treatment nash product candidate treatment hematologyoncology product candidate description product phase axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment second line diffuse large bcell lymphoma dlbcl product phase axicabtagene ciloleucel evaluate treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel axicabtagene ciloleucel evaluate treatment dlbcl combination antipdl mab line dlbcl tirabrutinib tirabrutinib btk inhibitor evaluate treatment bcell malignancy ktex car cell therapy evaluate treatment mantle cell lymphoma adult pediatric ktex acute lymphoblastic leukemia product phase kite kite mage aa evaluate treatment solid tumor product candidate treatment inflammationrespiratory disease product candidate description product phase filgotinib jak inhibitor evaluate treatment rheumatoid arthritis crohns disease ulcerative filgotinib colitis product phase filgotinib filgotinib evaluate treatment inflammatory disease gs gs syk inhibitor evaluate treatment sjogren syndrome lupus product phase gs gs tpl inhibitor evaluate treatment inflammatory bowel disease product candidate product candidate description product phase remdesivir remdesivir nuc inhibitor evaluate treatment ebola virus infection addition internal discovery clinical development program seek add portfolio product product acquisition inlicense strategic collaboration complete collaboration partnership strategic investment compare reflect commitment enable access new technology drug candidate potential evolve care people lifethreatene illness patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent phase product candidate product candidate fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hivaid eu descovy prep product candidate treatment liver disease selonsertib treatment nash product candidate treatment hematologyoncology axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma product candidate treatment inflammationrespiratory disease filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis application patent term extension file united states grant extend expiration date application supplementary protection certificate file european union grant extend eu expiration date composition matter patent expire european union european union united states patent application pende relate kite proprietary manufacturing process follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states european union primary typically compound patent principal product product fixeddose combination single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration eu letairis ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant note gilead watson laboratories inc reach agreement settle patent litigation matter relate letairis gilead lupin limited lupin reach agreement settle patent litigation matter relate ranexa gilead teva pharmaceuticals reach agreement settle patent litigation concern patent protect emtricitabine truvada atripla product supplementary protection certificate spc grant european country validity spc challenge generic manufacturer launch compete product validity spc consider national court court justice european union composition matter patent expire european union european union united states patent application pende relate kite proprietary manufacturing process application patent term extension pende united states andor spc pende country european union product application patent term extension file united states grant extend expiration date application spc file european union grant extend eu expiration date patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient api hiv product yescarta letairis ranexa hold party acquire exclusive right patent agreement party patent cover ranolazine active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level obtain patent formulation characteristic plasma level achieve obtain patent certain product year marketing approval obtain patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party reputation harm require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country provide effective enforcement patent thirdparty manufacturer able sell generic version product country description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material product manufacture facility thirdparty contract manufacturer depend party perform manufacturing activity majority api drug product product include hiv hcv product use multiple thirdparty contract manufacturer primary backup supplier manufacturing site letairis exclusive manufacturer ambrisentan api qualified supplier api yescarta establish clinical commercial manufacturing facility cell processing activity future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility lease manufacturing facility foster city san dimas la verne oceanside el segundo california dublin cork ireland edmonton alberta canada manufacture distribute certain product api clinical andor commercial use foster city california conduct process chemistry research development activity manufacture api clinical trial oversee party contract manufacturer san dimas la verne california manufacture ambisome san dimas package label majority commercial product distribute product america pacific rim oceanside california utilize facility clinical manufacture process development biologic candidates el segundo california utilize facility clinical commercial manufacture process yescarta cork dublin ireland utilize cork facility commercial manufacture packaging label antiviral product perform quality control testing labeling package final release product distribution european union international market dublin facility responsible distribution activity product edmonton alberta canada conduct process chemistry research scaleup activity clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process thirdparty manufacturer believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product require enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable information thirdparty manufacturer item risk factor manufacture problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency ema similar regulation effect jurisdiction manufacture operation subject routine inspection regulatory agency yescarta require fda comply risk evaluation mitigation strategy program include educate certify medical personnel therapy procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity additionally require maintain complex chain identity custody respect patient material material move manufacturing facility manufacturing process patient access raw material need access certain raw material conduct clinical trial manufacture product raw material generally available multiple source purchase worldwide normally available quantity adequate meet need business attempt manage risk associate supply chain inventory management relationship management evaluation alternative source feasible information item risk factor able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue seasonality operation backlog worldwide product sale reflect significant degree seasonality endus demand united states fluctuation wholesaler inventory level impact product sale observe strong wholesaler sub wholesaler purchase product fourth quarter result inventory drawdown wholesaler subwholesaler subsequent quarter factor include government budget annual grant cycle federal state fund buy pattern impact product sale record particular quarter information item risk factor inability accurately predict demand product uptake new product fluctuation customer inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states european union country include law regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume regulatory requirement applicable drug development approval subject change legal regulatory change impact operation future country regulatory agency fda united states emaeuropean commission european union approve drug sell respective country country general process drug approval united states summarize country include country european union similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial acceptable benefitrisk profile submit appropriate filing usually form new drug application nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california license state california compliance local regulatory requirement manufacture facilities canada ireland obtain local license permit compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite review european union approval process drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject substantial discount list price result price increase implement time time certain product limit effect product sale certain market addition standard reimbursement structure adequately reimburse innovative therapy product mature private insurer government payer reduce reimburse patient increase pressure reduce price new brand generic product introduce major market ability maintain pricing market share affect information item risk factor exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability inability accurately predict demand product uptake new product fluctuation customer inventory difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price patient assistance program recently enhance scrutiny companysponsore patient assistance program include insurance premium copay assistance program donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agents vendor donation recipient deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing patient support medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program healthcare reform federal state government continue propose pass legislation design regulate healthcare industry include legislation seeks indirectly directly regulate pharmaceutical drug pricing information item risk factor result operation adversely affect current potential future healthcare legislative regulatory action law regulation applicable health care industry impose new obligation require change business practice restrict operation future employee january approximately employee believe good relation employee environment subject number law regulation require compliance federal state local regulation protection environment regulatory landscape continue evolve anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position information subject information requirement exchange act file periodic report proxy information statement information sec sec maintains website httpwwwsecgov contain report proxy information statement information issuer file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filing section available follow filing free charge soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act transaction iran engage transaction iran require disclosure annual report item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale product treat hiv hcv unable increase hiv sale hcv sale decrease anticipate result operation adversely affect receive substantial portion revenue sale product treatment hiv infection year end december sale hiv product account approximately total product sale expect hiv product account high percentage total product sale hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain increase hiv product sale result operation likely suffer likely need scale operation include future drug development spending research development rd effort year end december sale product treatment chronic hepatitis c virus hcv infection account approximately total product sale hcv revenue decline expect decline product sale compare major market driver hcv product revenue patient start net pricing market share treatment duration treatment duration stabilizing pricing largely stabilize expect continue compete market share market segment geography anticipate patient start continue steadily decline predictable unexpected adverse change driver include large anticipate shift adversely impact hcv product revenue addition future sale hiv hcv product depend extent reimbursement product private public payer continue experience global pricing pressure result large discount rebate product delay reimbursement negatively impact product sale result operation private public payer choose exclude product formulary coverage list limit type patient coverage provide negatively impact demand revenue product change formulary coverage reimbursement level discount rebate offer product payer impact anticipate revenue unable achieve forecast hiv hcv sale stock price adversely impact unable sustain increase sale hiv hcv product number reason include limited reason discuss follow product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue product mature private insurer government payer reduce reimburse patient product increase pressure reduce price physician benefit hiv hcv product sale hiv hcv product limit new branded generic product introduce major market ability maintain pricing market share affect fail commercialize new product expand indication exist product prospect future revenue result operation adversely affect introduce new product increase sale exist product able increase maintain total revenue continue expand rd effort result operation adversely affect drug development inherently risky product candidate fail drug development process decide terminate product development expend significant resource effort example recently announce kite anti bcell maturation antigen antibcma evaluate treatment multiple myeloma move forward recently announce stellar phase study evaluate safety efficacy selonsertib patient compensate cirrhosis nonalcoholic steatohepatitis nash meet prespecifie week primary endpoint addition unable obtain regulatory approval product candidate future revenue growth result operation adversely impact future marketing application file approve regulatory authority timely basis marketing approval grant significant limitation use inability accurately predict demand product uptake new product fluctuation customer inventory make difficult accurately forecast sale cause forecast revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand depend number factor example nonretail sector united states include government institution include state aids drug assistance program adap department veteran affair correctional facility large health maintenance organization tend consistent term buy pattern cause quarteroverquarter fluctuation necessarily mirror patient demand product federal state budget pressure annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future sell distribute product united states exclusively wholesale channel year end december approximately product sale united states wholesaler amerisourcebergen corp cardinal health inc mckesson corp wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition increase competition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesalers order end user demand change example fourth quarter strong wholesaler sub wholesaler purchase product result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition estimate rebate require pay connection sale particular quarter base claim datum prior quarter united states actual rebate claim typically payer quarter arrear actual claim vary significantly estimate cause adjustment product revenue extent actual anticipate product revenue exceed fall short investor expectation stock price adversely impact yescarta chimeric antigen receptor car cell therapy represent novel approach cancer treatment create significant challenge impact ability increase sale yescarta yescarta car cell therapy involve harvesting cell patient blood ii engineering cell express cancerspecific receptor iii increase number engineer cell iv infuse functional cancerspecific cell patient advance novel personalize therapy create significant challenge include educate certify medical personnel procedure potential effect profile therapy potential adverse effect relate cytokine release syndrome neurologic toxicity compliance risk evaluation mitigation strategy rem program require fda yescarta medicine manage adverse effect therapy tocilizumab corticosteroid available sufficient quantity adequately control effect andor detrimental impact efficacy treatment develop robust reliable process limit contamination risk engineering patient cell ex vivo infuse engineer cell patient conditioning patient chemotherapy advance administer therapy increase risk adverse effect use engineer cell potential cancer treatment recent development broadly accept physician patient hospital cancer treatment center payer medical community able establish demonstrate medical community commercial governmental payer safety efficacy yescarta potential advantage compare exist future therapeutic fail overcome significant challenge sale yescarta result operation stock price adversely affect face significant competition face significant competition global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing tafcontaine hiv product compete primarily product viiv healthcare company viiv face competition generic hiv product generic version efavirenz component atripla available united states canada europe observe pricing pressure relate efavirenz component atripla sale tdf active pharmaceutical ingredient truvada atripla compleraeviplera stribild face generic competition european union united states certain country addition emtricitabine active pharmaceutical ingredient truvada face generic competition european union truvada face generic competition european union certain country outside united states hcv product compete primarily product market abbvie merck hbv product face competition exist therapy treat patient hbv generic version tdf hbv product compete product market bristolmyer squibb company novartis pharmaceutical corporation novartis yescarta compete car cell therapy market novartis expect compete product company develop advanced cell therapy letairis compete product market actelion pharmaceutical inc united therapeutics corporation pfizer inc patent ambrisentan active pharmaceutical ingredient letairis expire july letairis expect face competition manufacturer generic version letairis united states ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate ranexa expect face competition manufacturer generic version ranexa united states start quarter addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share result new technology commercialization strategy adversely affect result operation stock price result operation adversely affect current potential future healthcare legislative regulatory action legislative regulatory action affect government prescription drug procurement reimbursement program occur relatively frequently united states affordable care act aca enact expand healthcare coverage numerous effort repeal amend administratively limit aca example tax cut job act sign law president trump repeal individual health insurance mandate consider key component aca december texas federal district court strike aca ground individual health insurance mandate unconstitutional ruling stay pende appeal ongoing challenge aca result uncertainty future viability destabilization health insurance market result impact business uncertain material effort control prescription drug price material adverse effect business example president trump secretary department health human service hhs release american patient blueprint begin implement certain portion initiative include proposal increase generic drug biosimilar competition enable medicare program negotiate drug price directly improve transparency drug price way low consumer outofpocket cost trump administration propose establish international pricing index benchmark determine cost drug medicare b addition state propose enact legislation seeks indirectly directly regulate pharmaceutical drug pricing require biopharmaceutical manufacturer publicly report proprietary pricing information place maximum price ceiling pharmaceutical product purchase state agency example california governor sign prescription drug price transparency state bill law require prescription drug manufacturer provide advance notice explanation price increase certain drug exceed specify threshold similar bill introduce federal level initiative legislation cause add pricing pressure product change medicaid program federal state level material adverse effect business proposal impact coverage reimbursement product include give state flexibility manage drug cover medicaid program permit reimportation prescription medication canada country material adverse effect limit product use coverage furthermore state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate extent private insurer manage care program follow medicaid coverage payment development use enactment increase rebate exert pricing pressure product adverse effect magnify adoption low payment schedule propose regulatory action affect manufacturer material adverse effect business example december hhs propose rule modify medicare protect class policy provide plan sponsor broad authority impose step therapy prior authorization utilization management control product protect class include hiv product january hhs propose rule remove regulatory protection discount safe harbor federal antikickback statute manufacturer rebate pay plan sponsor medicaid manage care organization pharmacy benefit manager contract create new safe harbor arrangement entity difficult predict impact propose legislative regulatory action result state action use reimbursement product united states result operation adversely affect exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service substantial portion sale majority product subject significant discount list price addition standard reimbursement structure adequately reimburse innovative therapy example effective october center medicare medicaid services cms establish inpatient reimbursement patient receive yescarta reimbursement include payment severity adjust diagnosis relate group drg new technology addon payment ntap yescarta cover half cost yescarta cover case outli payment take total payment sufficient reimburse hospital cost care patient receive yescarta payment methodology likely effect september limited payment impact willingness hospital offer therapy doctor recommend therapy lessen attractiveness therapy patient adverse effect sale yescarta result operation cms propose national coverage decision car cell impose certain coverage limitation therapy coverage limitation apply entire medicare program include thing requirement patient enrol clinical trial registry order hospital physician pay car cell therapy commercial payer follow medicare coverage policy impose similar limitation additionally european union barrier reimbursement individual country limit uptake yescarta law regulation applicable health care industry impose new obligation require change business practice restrict operation future health care industry subject federal state international law regulation pertain drug reimbursement rebate price report health care fraud abuse datum privacy security united states law include antikickback false claim law law regulation relate medicare medicaid programs federal state program medicaid rebate statute individual state law relate pricing sale marketing practice health insurance portability accountability act hipaa federal state law relate privacy security health information violation law relate regulation punishable criminal andor civil sanction include instance substantial fine civil monetary penalty exclusion participation federal state health care program include medicare medicaid veterans administration health program federal employee health benefit program action executive oversee business burdensome remediation measure addition law regulation broad scope subject change evolving interpretation require incur substantial cost associate compliance alter sale marketing practice violation law allegation violation result negative publicity consequence harm reputation disrupt business adversely affect result operation event occur business stock price materially adversely affect recently enhance scrutiny companysponsore patient assistance program include insurance premium copay assistance program donation thirdparty charity provide assistance enhance scrutiny government reimbursement support offering clinical education program promotional speaker program agents vendor donation recipient deem fail comply law regulation government guidance area subject criminal civil sanction similar violation competitor negatively impact industry reputation increase scrutiny business product description government investigation relate litigation note commitment contingency note consolidated financial statement include item annual report engage future engage business acquisition license arrangement strategic collaboration disposal asset cause incur significant expense adversely affect financial condition result operation engage future engage business acquisition license arrangement strategic collaboration disposal asset business strategy identify suitable transaction future complete transaction timely manner cost effective basis realize expect benefit successful make acquisition product technology acquire successful require significantly great resource investment originally anticipate able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability conduct annual impairment testing goodwill indefinite live intangible asset fourth quarter early impairment indicator exist require generally accept accounting principle fail overcome risk cause incur significant expense negatively affect profitability adverse effect result operation experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment longterm asset approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay foreign currency exchange net hedge favorable impact product sale million year end december compare period predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar significant safety issue arise market product product candidate reputation harm future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation fda european medicines agency ema comparable regulatory agency country continue clinical trial product currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture safety report promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement rem product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose fda result significant civil monetary penalty operating result adversely affect face risk clinical trial include potential unfavorable result delay anticipate timeline disruption adversely affect prospect future revenue growth result operation require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product example recently announce kite antibcma evaluate treatment multiple myeloma move forward recently announce stellar phase study evaluate safety efficacy selonsertib patient compensate cirrhosis nash meet prespecifie week primary endpoint product candidate fail achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth result operation adversely impact example face numerous risk uncertaintie product candidate include descovy preexposure prophylaxis prep selonsertib treatment nash axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize example fda request conduct safety study filgotinib man ulcerative colitis manta study enrollment manta study likely rate limiting factor file nda filgotinib united states strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth result operation adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn adversely affect result operation harm business addition extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent thirdparty contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit train program management patient enrollment ongoing monitoring site management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship party sale marketing performance technology development logistic commercialization product failure maintain relationship poor performance company dispute party negatively impact business rely number collaborative relationship party sale marketing performance certain territory example collaboration arrangement janssen sciences ireland uc odefsey compleraeviplera symtuza country rely international distributor sale certain product relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline addition rely party site collect patient white blood cell know apheresis center shipper courier hospital logistical collection patient white blood cell ultimate delivery yescarta patient disruption difficulty incur vendor result product loss regulatory action harm yescarta business reputation ensure apheresis center prepare ship cell manufacture facility plan conduct quality certification apheresis center apheresis center choose participate certification process unable complete certification timely manner delay restrain manufacturing commercialization effort result sale yescarta limit harm result operation success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret internal knowhow defend infringement patent effort invalidate operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application addition competitor file patent application cover technology participate litigation postgrant proceeding patent trademark office proceeding determine right patent validity patent grant litigation postgrant proceeding patent trademark office proceeding unpredictable expensive divert management attention operation ultimately successful result operation adversely affect event generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application process typically manufacturer seek approval generic drug description anda litigation note commitment contingency note consolidated financial statement include item annual report entry generic version product lead market share price erosion negative impact business result operation success depend large ability operate infringe patent proprietary right party infringe valid patent party require pay significant monetary damage prevent commercialize product require obtain license party able obtain alternative technology require license commercially reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent patent application own party party claim cover use sofosbuvir axicabtagene ciloleucel bictegravir description litigation sofosbuvir axicabtagene ciloleucel bictegravir note commitment contingency note consolidated financial statement include item annual report aware patent nos assign department health human service purport claim process protect primate host infection immunodeficiency retrovirus administer combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus contact department health human service scope relevance patent explain believe patent valid patent office give relevant prior art physician patient claim method year center disease control prevention file application patent furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor certain party comply confidentiality agreement adequate remedy breach trade secret internal knowhow technological innovation know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret internal knowhow technological innovation confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect jurisdiction thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product able locate additional replacement facility reasonable basis sale product adversely impact reliance limit number facility extent risk materialize affect performance obligation financial result adversely affect manufacturing operation subject routine inspection regulatory agency unable remedy deficiency cite fda inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name new drug application marketing authorization application file regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility able replace timely manner commercially reasonable term problem single supplier depend include event disaster earthquake equipment failure difficulty negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product supply thirdparty manufacturer corporate partner outside united states result political economic factor specific country region include change interpretation trade regulation compliance requirement tax legislation limit prevent party outside united states supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result encounter difficulty ability provide product product candidate patient jeopardized import country product available low price unapprove generic counterfeit version product negative impact reputation business price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market hiv hbv hcv product agree available substantially reduce price certain low middleincome country participate gilead access program export low middleincome country united states europe high price market revenue adversely affect addition enter voluntary licensing agreement generic drug company india south africa china licensing agreement medicine patent pool unite nationsbacke public health organization allow generic drug company manufacture generic version hiv hbv product incorporate licensed compound taf cobicistat elvitegravir bictegravir distribution certain low middleincome country enter agreement generic manufacturers india egypt pakistan allow produce andor distribute generic version hcv product certain low middle income country generic version hiv hbv hcv product produce andor distribute agreement reexporte united states europe market outside low middleincome country revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter additionally use divert product occur country approve patient source product outside legitimate supply chain product handled ship store inappropriately affect efficacy product harm patient brand commercial scientific reputation product european union require permit product purchase eu member state sell eu member state purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business aware existence buyer club world promote personal importation generic version hcv hiv product approve use country import result patient risk take unapproved medication purport potency claim contain harmful substance extent patient unapproved generic version medication injure generic product brand commercial scientific reputation hcv hiv product harm party illegally distribute sell counterfeit version product meet rigorous quality standard manufacturing supply chain example report product label epclusa available multiple country determine authentic product base sample analysis lot number cooperate continue cooperate regulatory authority investigate matter actively action discourage counterfeit product world include work local regulatory legal authority enforce law counterfeit drug raise public awareness danger counterfeit drug promote public policy hinder sale availability counterfeit drug counterfeit drug pose risk patient health safety raise risk product recall reputation business suffer result counterfeit drug sell brand expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning require significant management attention description litigation investigation disputerelate matter note commitment contingency note consolidated financial statement include item annual report outcome legal proceeding legal proceeding bring investigation investigation initiate disputerelate matter inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business face significant liability result product liability materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company limited insurance product liability arise maintain adequate coverage claim exceed coverage financial condition adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition description product liability matter note commitment contingency note consolidated financial statement include item annual report fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term additionally change immigration work authorization law regulation difficult employee work transfer jurisdiction operation impair ability attract retain qualified personnel unsuccessful recruitment retention effort business harm end john f milligan step president chief executive officer follow year service announce daniel p serve chief executive officer effective march successfully manage transition new chief executive officer business negatively impact business disruption natural manmade disaster harm future revenue worldwide operation party manufacturer corporate partner subject business interruption stem natural manmade disaster include related climate change uninsured inadequately insure corporate headquarters foster city santa monica location house majority rd activity san dimas la verne oceanside el segundo manufacturing facility locate california seismically active region carry adequate earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake dependent information technology system infrastructure datum subject cyberattack security breach dependent information technology system infrastructure datum include kite konnect platform critical ensure chain identity chain custody yescarta multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business technology partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort effort partner vendor prevent service interruption identify breach system interruption breach adversely affect business operation andor cause loss critical sensitive information result financial legal business reputational harm addition insurance sufficient type cover financial legal business reputational loss result interruption breach system regulator globally impose new datum security requirement include great monetary fine privacy violation example general datum protection regulation gdpr effective europe establish new regulation handle personal datum noncompliance gdpr result monetary penalty percent worldwide revenue addition subject additional data privacy security law california consumer privacy act gdpr change law regulation associate enhance protection certain type sensitive datum include healthcare datum personal information greatly increase cost provide product service prevent offer certain service jurisdiction operate change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative regulatory change material adverse impact result operation example united states enact significant tax reform certain provision new law complex continue significantly affect addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited change forecast demand hcv product portion nontax deductible annual brand prescription drug fee accounting stock option sharebase award merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit future level rd spending change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits potential change legal entity structure impact income tax provision result mention factor significant negative impact consolidate result operation income tax return subject audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period note income taxis note consolidated financial statement include item annual report additional detail assurance pay dividend continue repurchase stock board director authorize dividend program intend pay quarterly dividend share subject quarterly declaration board director board director approve repurchase billion common stock billion available repurchase december future declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing rd activity rd facility emeryville oceanside santa monica california gaithersburg maryland seattle washington edmonton alberta canada amsterdam netherlands manufacturing facility el segundo la verne oceanside san dimas california alberta canada dublin cork ireland global operation include office europe north america asia south america africa australia middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report incorporate reference item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index sp index nasdaq biotechnology index nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year note section solicit material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december assume dividend reinveste equity compensation plan information follow table provide certain information respect equity compensation plan effect december number common share remain available issuance weightedaverage equity number common share exercise price compensation plan issue exercise outstanding option exclude security outstanding option warrant warrant right reflect column rights b c plan category thousand dollar thousand equity compensation plan approve security holder equity incentive plan employee stock purchase plan total equity compensation plan approve security holder equity compensation plan approve security holder total note account million restrict stock stock unit award performance share unit phantom share grant equity incentive plan employee stock purchase plan participant permit purchase common stock discount certain date payroll deduction predetermine purchase period accordingly number determinable issuer purchase equity security quarter board director authorize billion share repurchase program program repurchase open market privately negotiate transaction start repurchase program april repurchase retire million share common stock billion open market transaction program table summarize stock repurchase activity month end december maximum fair total number value share total number average share purchase share price pay publicly purchase purchase share announce program program thousand dollar thousand million october october november november december december total note difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock unit award order satisfy applicable tax withholding obligation item select financial datum gilead sciences inc select consolidated financial datum million share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share december consolidated balance sheet datum cash cash equivalent marketable debt security work capital total asset longterm obligation longterm debt include current portion retain earning total stockholder equity note management discussion analysis financial condition result operation include item annual report description result operation adopt accounting standard update topic revenue contract customer modify retrospective method apply contract complete january result present topic information prior period adjust continue report accordance historical accounting topic revenue recognition impact result apply topic place topic material year end december note organization summary significant accounting policy note revenue note consolidated financial statement include item annual report information december record estimate billion net charge relate enactment tax cut job act note income taxis note consolidated financial statement include item annual report additional detail repay billion principal senior unsecured note maturity repay billion term loan borrow connection acquisition kite pharma inc kite fi c l c ri en ic gn ec et mio enn w oi ft wh hth ice h cq u bi li lo f w k asit e pw ae d insu de ec em b e b r l li n aggregate principal senior unsecured note register offering draw billion aggregate principal term loan pin r n ci p l w bae l ais ns cu ee od f e n io b r ul nli en c rr ei dn c ni op ta el dm uo eu not ef cs ee mn bio er r u n se c ured note register offering repay million principal balance convertible senior note million issue billion principal senior unsecured note register offering repay million principal balance convertible senior note bin l n ce w f se e n ou ud n se c u rb ei dl l nio te p r din uc ei ip na l em co emun bt e ro f se n anr du n e c u r me il ln ioo nte nin er g oi rt e fir ed yo eff ae rr rn evg os l vw ine g l cs ro ed r ie tp fa ai cd il g rm ei el mli eo nn principal balance convertible senior note million principal retrospectively adopt accounting standard update balance sheet classification defer taxis require defer tax asset liability classify noncurrent balance sheet result reclassify defer tax asset total current asset longterm asset defer tax liability accrue liability longterm obligation year present retrospectively adopt accounting standard update simplifying presentation debt issuance cost require presentation debt issuance cost direct deduction carrying recognize debt liability balance sheet result reclassify unamortized debt issuance cost asset longterm debt include current portion year present item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescarta zydelig sell distribute certain product corporate partner collaborative agreement business highlight mark operational excellence transition position future growth business continue develop deliver innovative medicine help people lifethreatene illness world highlight performance include hiv achieve record sale hiv product hiv product revenue increase united states worldwide compare growth drive successful launch biktarvy continue strong uptake single tablet regimen contain tenofovir alafenamide taf treatment hiv infection truvada preexposure prophylaxis prep indication hiv prevention biktarvy oncedaily single tablet regimen contain bictegravir emtricitabine ftc taf treatment hiv infection adult approve food drug administration fda february european commission june liver disease revenue chronic hepatitis c virus hcv product predictable want introduce lower price alternative hcv product significant disruption healthcare system business authorize launch generic version epclusa harvoni united states start january separate subsidiary asegua therapeutics llc asegua continue advance clinical trial treatment chronic hepatitis b virus hbv nonalcoholic steatohepatitis nash include complete enrollment phase clinical trial nash cell therapy immunooncology advanced pipeline cancer therapy position leader cell therapy yescarta approve european commission august treatment relapse refractory diffuse large bcell lymphoma dlbcl primary mediastinal large bcell lymphoma pmbcl line systemic therapy certify additional center united states europe provide treatment yescarta order advance accelerate research development effort cell therapy immunooncology year enter key strategic collaboration national cancer institute pfizer inc pfizer sangamo therapeutics inc sangamo gadeta bv gadeta hifibio therapeutics hifibio tango therapeutics tango agenus inc agenus inflammation continue advance pipeline novel investigational agent inflammatory disease include announce positive datum filgotinib ongoing phase clinical trial enter strategic collaboration verily life sciences llc alphabet company verily verilys immunoscape platform identify well understand immunological basis inflammatory disease year continue invest advance research development pipeline therapeutic area end research development pipeline include active clinical study phase clinical trial additionally complete collaboration partnership strategic investment reflect commitment enable access new technology drug candidate potential evolve care people lifethreatene illnesse investment research development reflect commitment expand pipeline range disease address area significant unmet medical need position longterm growth business recent key announcement include hiv liver disease program fda european commission grant marketing authorization biktarvy treatment hiv infection fda approve truvada combination safe sex practice reduce risk sexually acquire hiv atrisk adolescent china national drug administration cda succeed china national medical product administration nmpa approve genvoya china treatment hiv infection nmpa approve descovy china treatment hiv infection adult adolescent enter agreement japan tobacco inc japan tobacco expand right develop commercialize elvitegravir include japan acquire japan tobacco right market distribute certain product hiv portfolio japan effective january enter research collaboration license agreement hookipa biotech ag hookipa grant exclusive right hookipas therat vaxwave arenavirus vectorbase immunization technology chronic hbv infection hiv infection announce plan launch authorize generic version epclusa harvoni united states separate subsidiary asegua nmpa approve harvoni china treatment chronic hcv infection genotype adult adolescent aged year cda approve epclusa china treatment adult genotype chronic hcv infection cda approve epclusa combination ribavirin adult chronic hcv infection decompensate cirrhosis nmpa approve vemlidy china treatment chronic hbv infection adult adolescent enter strategic collaboration precision bioscience precision develop therapy target vivo elimination chronic hbv infection precision proprietary genome editing platform arcus announce stellar phase randomize doubleblind placebocontrolle study evaluate safety efficacy selonsertib investigational oncedaily oral inhibitor apoptosis signalregulating kinase ask patient compensate cirrhosis f nash meet prespecifie week primary endpoint stage histologic improvement fibrosis worsen nash oncology cell therapy program enter immunooncology partnership agenu focus development commercialization novel immunooncology therapy enter global strategic collaboration tango discover develop commercialize pipeline target immunooncology treatment patient cancer european commission grant marketing authorization yescarta treatment adult patient relapse refractory dlbcl pmbcl line systemic therapy announce new worldwide facility advance manufacturing cell therapie people cancer enter research collaboration gadeta advance gamma delta cell receptor technology solid tumor collaboration add additional new platform current capability research cell manufacturing enter research collaboration license agreement hifibio develop technology support discovery neoantigenreactive cell receptor potential treatment cancer include solid tumor enter license agreement trianni inc trianni grant use trianni transgenic human monoclonal antibody discovery platform support drug discovery effort announce new cooperative research development agreement national cancer institute develop adoptive cell therapy target patientspecific tumor neoantigen enter worldwide collaboration sangamo sangamos zinc finger nuclease technology platform development nextgeneration ex vivo cell therapy oncology enter clinical trial collaboration pfizer evaluate safety efficacy investigational combination yescarta pfizer utomilumab fully humanize bb agonist monoclonal antibody patient refractory large bcell lymphoma inflammation program enter strategic collaboration scholar rock hold corporation discover develop highly specific inhibitor transform growth factor beta activation treatment fibrotic disease enter scientific collaboration verily verilys immunoscape platform identify well understand immunological basis common inflammatory disease rheumatoid arthritis inflammatory bowel disease lupusrelated disease transition follow year service john f milligan phd step role president chief executive officer ceo effective december board announce selection daniel oday new chairman ceo effective march mr oday bring year executive management creative leadership operational excellence recently mr oday serve ceo roche pharmaceutical pharma division roche group leadership transition year result plan succession normal industry turnover financial highlight total revenue decrease billion total product sale decrease billion compare billion billion respectively primarily low sale hcv product partially offset high sale hiv product united states product sale billion compare billion europe product sale billion compare billion product sale international location billion compare billion cost good sell increase billion compare billion primarily reserve excess raw material inventory high amortization relate intangible asset acquire connection acquisition kite pharma inc kite inventory reserve million record excess raw material primarily sustained decrease demand harvoni result shift market harvoni epclusa research development rd expense increase billion compare billion primarily million impairment charge relate inprocess rd iprd kite program antibcma evaluate treatment multiple myeloma increase upfront collaboration expense enhance pipeline year investment support growth business follow acquisition kite higher stockbase compensation expense associate acquisition kite sell general administrative sga expense increase billion compare billion primarily year investment support growth business follow acquisition kite partially offset low acquisitionrelate cost associate acquisition kite lower brand prescription drug bpd fee net income attributable gilead billion diluted share compare billion diluted share increase primarily billion charge income tax expense relate enactment tax cut job act tax reform record high hiv product sale partially offset low hcv product sale high operating expense associate advancement pipeline investment support growth business follow acquisition kite december billion cash cash equivalent marketable debt security compare billion december generate billion operating cash flow repay billion principal debt pay cash dividend billion repurchase total million share billion open market transaction outlook expect continue maintain strong focus operational excellence financial discipline rd perspective expect continue invest new ongoing clinical study support exist product product candidate expect datum readout include selonsertib stellar treatment nash filgotinib treatment rheumatoid arthritis descovy prep indication order augment product pipeline continue pursue opportunity collaboration partnership strategic investment fit long term strategic plan commercial perspective expect continue promote biktarvy hiv regimen contain taf addition believe truvada prep continue integral growth hiv united states community continue embrace public health benefit prevention hcv expect decline product sale result low patient start market competitive factor low rate believe launch authorize generic version epclusa harvoni united states separate subsidiary asegua increase access medication patient low price cell therapy expect continue promote yescarta united states support launch europe continue help promote patient access product world include gilead access program million people receive hiv medicine low middleincome country progress initiative subject number uncertainty include limited possibility unfavorable result new ongoing clinical trial example recently announce stellar phase study evaluate safety efficacy selonsertib patient compensate cirrhosis nash meet prespecifie week primary endpoint continuation uncertain global macroeconomic environment additional pricing pressure payer competitor slow anticipate growth hiv product increase discount chargeback rebate ongoing contract future negotiation commercial government payer market share price erosion cause introduction generic version product contain tenofovir disoproxil fumarate tdf outside united states viread letairis ranexa united states inaccuracy hcv patient start estimate potential amendment affordable care act government action effect lower price large thananticipate shift payer mix highly discount payer segment volatility foreign currency exchange rate result operation total revenue follow table summarize periodoverperiod change product sale royalty contract revenue million percentage change change revenue product sale royalty contract revenue total revenue january adopt accounting standard update revenue contract customer topic modify retrospective method apply contract complete january result present topic information prior period adjust continue report accordance historical accounting topic revenue recognition topic impact result apply topic place topic material year end december note organization summary significant accounting policy note revenue note consolidated financial statement include item annual report information product sale compare total product sale decrease billion compare billion primarily low sale hcv product partially offset increase sale hiv product hiv product sale increase billion compare billion primarily launch biktarvy continue uptake descovy genvoya odefsey hcv product sale decrease billion compare billion primarily low average net selling price low sale volume major market result increase competition low patient start yescarta generate million sale compare million sale product sale include product hbv cardiovascular oncology category inclusive vemlidy viread letairis ranexa zydelig ambisome decrease billion compare billion sale viread primarily treatment chronic hbv infection decrease availability generic version product letairis expect face generic competition united state patent ambrisentan active pharmaceutical ingredient letairis expire july ranexa expect face generic competition united states expect decline letairis ranexa sales united states generic entry total product sale generate outside united states face exposure movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge favorable impact product sale million compare record product sale net estimate mandatory supplemental discount government payer addition discount private payer include rebate chargeback cash discount prompt payment distributor fee relate cost deduction generally refer grosstonet deduction total billion gross product sale compare billion gross product sale billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost product sale united states decrease billion compare billion decrease primarily low sale hcv product partially offset high sale hiv product decrease sale hcv product primarily low average net selling price low sale volume result increase competition increase sale hiv product primarily launch biktarvy continue uptake descovy genvoya odefsey increase usage truvada prep high average net selling price partially offset decrease sale volume atripla complera stribild product sale europe decrease billion compare billion decrease primarily low sale hcv product availability generic version truvada atripla viread decrease sale hcv product primarily low sale volume average net selling price result increase competition decrease partially offset launch biktarvy continue uptake descovy genvoya odefsey foreign currency exchange net hedge favorable impact product sale europe million compare product sale international location decrease billion compare billion primarily low sale hcv product japan sale hcv product japan decrease million compare million primarily low market share result increase competition compare total product sale decrease billion compare billion primarily low sale hcv product partially offset increase sale hiv product hiv product sale increase billion compare billion primarily drive continued uptake descovy genvoya odefsey partially offset decrease sale truvada atripla complera stribild hcv product sale decrease billion compare billion primarily decline major market result increase competition low total market patient start product sale include product hbv cardiovascular oncology category inclusive vemlidy viread letairis ranexa zydelig ambisome increase billion compare billion total product sale generate outside united states face exposure movement foreign currency exchange rate primarily euro foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact product sale million compare grosstonet deduction total billion gross product sale compare billion gross product sale billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost product sale united states decrease billion compare billion decline sale hcv product partially offset increase sale hiv product decline sale hcv product primarily lower harvoni sovaldi sale volume result increase competition low total market patient start additionally increase epclusa vosevi sale volume partially offset low average net selling price epclusa pricing regimen gravitate week regimen price increase sale hiv product primarily continued uptake descovy genvoya odefsey high average net selling price partially offset decrease truvada atripla complera stribild prior year favorable impact revision rebate reserve million primarily relate truvada atripla complera stribild product sale europe decrease billion compare billion primarily lower harvoni sovaldi sale volume partially offset high epclusa sale volume foreign currency exchange net hedge unfavorable impact product sale europe million compare product sale international location decrease billion compare billion primarily low sale japan sale hcv product japan decrease million compare billion primarily low sale volume result low total market patient start increase competition follow table summarize periodoverperiod change product sale million percentage change change atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv ambisome epclusa harvoni letairis ranexa vemlidy viread vosevi yescarta zydelig total product sale note percentage meaningful include emtriva tybost represent revenue cobicistat c ftc taf symtuza darunavircftctaf fix dose combination product commercialize janssen include cayston hepsera sovaldi follow additional discussion result certain product descovy ftctafbase product biktarvy descovy genvoya odefsey product sale descovy ftctafbase product billion billion billion total product sale respectively sale descovy ftctafbase product billion united states billion europe compare billion united states million europe billion united states million europe increase compare major market primarily drive high sale volume reflect launch biktarvy continue uptake genvoya odefsey descovy increase compare major market primarily drive high sale volume patient shift away truvada ftctdfbase regimen truvada ftctdfbase product atripla compleraeviplera stribild truvada product sale truvada ftctdfbase product billion billion billion total product sale respectively sale truvada ftctdfbase product billion united states million europe compare billion united states billion europe billion united states billion europe united states decrease compare primarily low sale volume result patient switch new regimen contain taf partially offset increase usage truvada prep high average net selling price certain truvada ftctdf base product europe decrease compare primarily low sale volume result availability generic version truvada atripla patient switch new regimen contain taf united states decrease compare primarily low sale volume result patient switch new regimen contain taf partially offset increase usage truvada prep europe decrease compare primarily low sale volume result availability generic version truvada country patient switch new regimen contain taf hcv product epclusa harvoni sovaldi vosevi hcv product sale billion billion billion total product sale respectively sale hcv product billion united states million europe million international location sale hcv product billion united states billion europe billion international location sale hcv product billion united states billion europe billion international location decrease compare major market primarily low sale volume low average net selling price result increase competition low total market patient start harvoni sovaldi product sale decrease result shift market harvoni sovaldi epclusa decrease compare major market primarily low sale volume low average net selling price result increase competition low total market patient start harvoni sovaldi product sale decrease result shift market harvoni sovaldi epclusa epclusa product sale increase compare primarily year sale epclusa approve fda european commission june july respectively cost good sell product gross margin follow table summarize periodoverperiod change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin cost good sell increase million compare primarily high inventory reserve record inventory reserve million million relate excess raw material primarily sustained decrease demand harvoni result shift market harvoni epclusa inventory reserve record year end december material cost good sell increase year amortization expense relate intangible asset acquire connection acquisition kite october increase partially offset low cost efavirenz component atripla result termination collaboration arrangement bristolmyers squibb company december decrease product gross margin compare primarily factor impact cost good sell note change product mix decrease product gross margin compare primarily change product mix hcv product sale decrease percentage total product sale research development expense follow table summarize periodoverperiod change rd expense million percentage change change rd expense rd expense consist primarily clinical study perform contract research organization material supplies license fee upfront milestone payment collaboration agreement personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review rd pipeline status development necessary reallocate resource rd portfolio believe good support future growth business follow table provide breakout rd expense major cost type million clinical study outside service personnel infrastructure expense iprd impairment charge upfront collaboration expense acquire iprd stockbase compensation expense total rd expense increase billion compare primarily million impairment charge relate iprd kite program discontinuance increase upfront collaboration expense high personnel facilitiesrelate cost support growth business follow acquisition kite partially offset higher acquire iprd expense result purchase cell design labs inc rd expense decrease billion compare primarily impact business development activity result collaboration expense relate license collaboration agreement galapagos nv acquire iprd expense relate purchase nimbus apollo inc iprd impairment charge ongoing milestone payment partially offset acquire iprd expense relate purchase cell design labs inc sell general administrative expense follow table summarize periodoverperiod change sga expense million percentage change change sga expense sga expense relate sale marketing finance human resource legal administrative activity expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include bpd fee united states pharmaceutical manufacturer brand drug product require pay portion bpd fee estimate base select government sale prior year percentage total industry government sale truedup receipt invoice internal revenue service sga expense increase million compare primarily year expense support growth business follow acquisition kite partially offset low acquisitionrelate cost associate acquisition kite low bpd fee sga expense increase million compare primarily cost associate acquisition kite primarily consist stockbased compensation transaction cost high bpd fee expense result favorable adjustment million quarter bpd fee expense million million million respectively bpd fee expense taxdeductible income expense net income expense net million million million respectively increase compare primarily unrealized gain change fair value marketable equity security start january record unrealized gain loss change fair value marketable equity security income expense net consolidated statement income result adoption accounting standard update financial instrumentsoverall recognition measurement financial asset financial liability note organization summary significant accounting policy note consolidated financial statement include item annual report information increase income expense net compare primarily cash cash equivalent marketable security earn high yield high cash balance provision income taxis provision income taxis billion compare billion effective tax rate decrease effective tax rate primarily billion net tax charge reduction corporate tax rate result enactment tax reform december addition effective tax rate decrease million tax benefit record relate settlement tax examination offset million defer tax charge result transfer acquire intangible asset wholly own subsidiary change geographic mix earning tax global intangible lowtaxed income enact tax reform continue evaluate certain change legal entity structure response guideline requirement international tax jurisdiction conduct business change multiple reporting period implement result certain material nonrecurre adjustment defer tax asset andor liability cause offset increase decrease tax provision estimate adjustment reasonably determine time dependent change actually implement provision income taxis billion compare billion effective tax rate increase effective tax rate primarily enactment tax reform december change geographic mix earning contribute increase effective tax rate note income taxis note consolidated financial statement include item annual report additional detail tax reform liquidity capital resource follow table summarize cash cash equivalent marketable debt security working capital million december cash cash equivalent marketable debt security work capital cash cash equivalent marketable debt security cash cash equivalent marketable debt security decrease billion compare december generate billion operate cash flow repay billion principal senior unsecured note maturity repay billion term loan borrow connection acquisition kite pay cash dividend billion utilize billion stock repurchase working capital working capital increase billion compare december primarily drive increase cash cash equivalent result shift average remain term maturity marketable debt security portfolio reduce interest rate risk cash flow follow table summarize cash flow activity million cash provide operating activity invest activity financing activity cash provide operating activity cash provide operating activity represent cash receipt disbursement related activity invest financing activity operate cash flow derive adjust net income noncash item change operate asset liability cash provide operating activity decrease billion billion compare primarily low cash receipt result low product sale high tax payment tax payment include million payment relate annual installment tax reform transition tax million deem early payment tax reform transition tax million settlement tax examination cash provide operating activity decrease billion billion compare primarily low cash receipt result low product sale high tax payment cash provide investing activity cash provide investing activity primarily consist purchase sale maturity marketable debt security capital expenditure acquisition net cash acquire investment cash provide investing activity billion compare cash investing activity billion change cash provide investing activity primarily high proceed maturitie marketable debt security low purchase marketable debt security partially offset low proceed sale marketable debt security addition billion cash acquire kite cash acquisition cash investing activity increase billion billion compare primarily acquisition kite partially offset high proceed maturitie sale marketable debt security low purchase marketable debt security cash provide financing activity cash financing activity billion compare cash provide financing activity billion change cash provide financing activity primarily high repayment debt repurchase common stock addition billion net proceed debt issuance partially fund acquisition kite debt issue cash provide financing activity billion compare cash financing activity billion primarily low repurchase common stock high proceed issuance debt debt credit facility longterm obligation summary borrowing financing arrangement include note debt credit facility note consolidated financial statement include item annual report senior unsecured note repay maturity billion principal senior unsecured note issue september million principal senior unsecured note issue september connection acquisition kite issue billion aggregate principal senior unsecured note consist million principal float rate note september million principal float rate note march million principal float rate note september collectively float rate note billion principal senior note september fix rate note collectively float rate note note float rate note bear interest rate equal month london interbank offer rate libor plus respect float rate note september respect float rate note march respect float rate note september fix rate note pay interest semiannually float rate note pay interest quarterly require comply certain covenant note indentures december violation covenant term loan facility september enter billion aggregate principal term loan facility credit agreement consist billion principal day senior unsecured term loan facility billion principal threeyear senior unsecured term loan facility billion principal fiveyear senior unsecured term loan facility collectively term loan facility october draw billion aggregate principal term loan facility proceed finance acquisition kite billion repay remain billion repay term loan facility credit agreement terminate credit facility enter billion fiveyear revolve credit facility mature fiveyear revolve credit agreement revolve credit facility work capital requirement general corporate purpose include limitation acquisition require comply certain covenant fiveyear revolve credit agreement december violation covenant amount outstanding fiveyear revolve credit agreement capital return program detail stock repurchase program dividend include note stockholder equity note consolidated financial statement include item annual report additional information stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction start repurchase program april repurchase program million million share common stock billion million respectively december remain authorize repurchase program billion dividend declare pay quarterly cash dividend aggregate billion common share billion common share respectively february announce board director declare quarterly cash dividend increase share common stock payment date march stockholders record close business march future dividend subject declaration board director capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability possibility acquire additional manufacturing capability office facility possibility acquire company new product debt service requirement establishment additional collaborative relationship company cost associate defense settlement adverse result government investigation litigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement include item annual report prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition adoption asc topic revenue contract customer january adopt topic modify retrospective method result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic topic entity recognize revenue transfer control promise good service customer reflect consideration entity expect entitled exchange good service record cumulative effect apply new revenue standard net increase million opening balance retain earning impact result apply topic place topic material year end december product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party record product sale net estimate mandatory supplemental discount government private payer addition discount private payer relate charge generally account variable consideration estimate period relate sale occur government rebate chargeback represent majority variable consideration require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate aids drug assistance program rebate chargeback veterans administration public health service chargeback rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price allowance government rebate chargeback estimate base product sell historical payer mix pertinent thirdparty industry information estimate patient population know market event trend channel inventory datum andor market datum consider new information change program regulation guideline impact actual rebate andor expectation future payer mix program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate historically actual government rebate chargeback claim prior period vary estimate government chargeback payable direct customer classify reduction account receivable consolidated balance sheet total million million december respectively government rebate invoice directly record accrue government rebate consolidated balance sheet total billion billion december respectively follow table summarize consolidated activity end balance government rebate chargeback account million balance decreaseincrease balance end accrue government rebate chargeback begin year product sale payment year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total legal contingency party legal action significant describe note commitment contingency legal proceeding note consolidated financial statement include item annual report possible determine outcome matter recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss significant judgment require determination probability determination exposure reasonably estimable inherent uncertainty unpredictability relate matter accrual base believe good information available time assessment include legal fact circumstance case status proceeding applicable law view legal counsel final resolution matter possible loss excess record amount material adverse effect result operation cash flow financial position periodically reassess matter additional information available adjust estimate assumption fact circumstance indicate need change recognize accrual consolidated balance sheet matter december believe loss probable valuation intangible asset identifiable intangible asset measure respective fair value acquisition date subject revision measurement period year acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination information know knowable base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinite live amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinite live intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable october connection kite acquisition acquire intangible asset primarily related iprd axicabtagene ciloleucel kite antibcma evaluate treatment multiple myeloma ktex evaluate treatment adult pediatric acute lymphoblastic leukemia estimate aggregate fair value billion october fda approve axicabtagene ciloleucel know commercially yescarta make car cell therapy treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma transform follicular lymphoma primary mediastinal bcell lymphoma approval reclassify billion purchase iprd finitelive intangible asset amortize asset estimate useful life year straightline method fourth quarter conclude efficacy profile kite program justify effort base totality clinical datum gather decision discontinue kite program result estimate fair value iprd relate kite program write zero record impairment charge million research development expense consolidate statement income include item annual report provision income taxis estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination valuation allowance million million december respectively increase valuation allowance primarily related certain kite tax attribute certain foreign jurisdiction sufficient history profit realize benefit loss morelikelythannot basis subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law example united states enact significant tax reform certain provision new law continue significantly affect predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period total unrecognized tax benefit billion billion december recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit decrease approximately million month potential settlement tax authority file federal state foreign income tax return unite states foreign jurisdiction federal income tax purpose statute limitation open onwards onwards california income tax purpose certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position note income taxis note consolidated financial statement include item annual report additional information balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december million payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial transition tax payable total note debt consist senior unsecured note include principal interest payment interest payment fix rate senior unsecured note incur calculate base term relate note interest payment variable rate debt calculate base interest rate reset date debt instrument note debt credit facility note consolidated financial statement include item annual report additional information amount include capital project commitment primarily relate construction new building amount include purchase commitment primarily relate active pharmaceutical ingredient minimum purchase requirement certain inventoryrelate item amount include million accrue payment japan tobacco inc result collaboration arrangement note collaborative arrangement note consolidated financial statement include item annual report additional information addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure contract research organization cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract connection tax reform december record federal income tax payable transition tax mandatory deem repatriation foreign earning payable eightyear period amount include table represent remain federal income tax payable apply year installment payment early payment future installment note income taxis note consolidated financial statement include item annual report form k additional detail tax reform december longterm income taxis payable include unrecognized tax benefit interest penalty total billion high degree uncertainty time future cash settlement event extinguish unrecognized tax benefit unable estimate period cash settlement exclude unrecognized tax benefit table recent accounting pronouncement information require item include note organization summary significant accounting policy note consolidated financial statement include item annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk market price reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable debt security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset interestbeare liability december millions percentage expect maturity total fair total value asset availableforsale debt security average interest rate liability longterm debt include current portion fix rate average interest rate variable rate average interest rate note amount represent principal balance addition fix variable rate longterm debt billion fiveyear revolve credit facility amount outstanding fiveyear revolve credit facility december note debt credit facility note consolidated financial statement include item annual report additional information average interest rate variable rate debt base interest rate reset date debt instrument dependent factor subject change include limited libor principal debt outstanding credit rating reset date credit risk subject credit risk portfolio cash equivalent marketable debt security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past december account receivable net southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past date experience significant loss respect collection account receivable market price risk hold share common stock certain publicly trade biotechnology company connection license collaboration agreement equity security measure fair value change fair value recognize earning start january result adoption accounting standard update financial instrumentsoverall recognition measurement financial asset financial liability note organization summary significant accounting policy note consolidated financial statement include item annual report information fair value equity security approximately million million december respectively change fair value equity security primarily volatility stock market change general economic condition factor hypothetical increase decrease stock price equity security increase decrease fair value december approximately million million respectively item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement select quarterly financial information unaudite schedule ii valuation qualifying account report independent register public accounting firm shareholder board director gilead sciences inc opinion financial statement audit accompany consolidated balance sheet gilead sciences inc company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item collectively refer consolidated financial statement opinion consolidated financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states pcaob companys internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion ernst young llp serve company auditor san jose california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance respectively inventory prepaid current asset total current asset property plant equipment net longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note stockholder equity prefer stock par value share share authorize outstanding common stock par value share authorize share issue outstanding respectively additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net income loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain net tax impact respectively reclassification net income loss net tax impact respectively net change cash flow hedge net unrealized gain loss net tax impact respectively reclassification net income net tax impact respectively net change comprehensive income loss comprehensive income comprehensive income loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholders equity millions share amount gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare share reclassification conversion spread convertible note reclassification convertible note hedge reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share balance december change noncontrolle interest net income comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan stockbase compensation repurchase common stock dividend declare share cumulative effect adoption new accounting standard balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense defer income taxis inprocess research development impairment inventory reserve excess raw material change operate asset liability account receivable net inventory prepaid expense account payable income taxis payable accrue liability net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security investment acquisition net cash acquire capital expenditure net cash provide investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge proceed issuance common stock repurchase common stock repayment debt obligation payment settle warrant payment dividend net cash provide financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world operation country worldwide headquarters foster city california gileads primary area focus include hivaid liver disease hematologyoncology inflammationrespiratory disease seek add exist portfolio product internal discovery clinical development program product acquisition inlicense strategic collaboration portfolio market product include ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescarta zydelig sell distribute certain product corporate partner collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december material vie significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition january adopt accounting standard update revenue contract customer topic modify retrospective method topic supersede revenue recognition requirement topic revenue recognition topic result change accounting policy revenue recognition detailed policy election practical expedient take account shipping handling activity perform customer obtain control good fulfillment cost separate performance obligation expect contract inception period transfer control correspond payment customer year adjust consideration effect significant financing component product sale recognize revenue product sale control product transfer generally shipment delivery customer certain case correspond sale customer party recognition revenue product sale provision form variable consideration include government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate payment term customer generally range day variable consideration rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate aids drug assistance program rebate chargeback veterans administration public health service chargeback rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical payer mix available pertinent thirdparty industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future payer mix program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate invoice directly record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical customer payment pattern expectation future customer payment pattern distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country product expired accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty contract revenue royalty revenue recognize period obligation satisfied correspond sale corporate partner occur research development expense research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee upfront milestone payment collaboration arrangement overhead allocation consist support facilityrelate cost charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination sell general administrative expense sell general administrative sga expense relate sale marketing finance human resource legal administrative activity sga expense consist primarily personnel cost facility overhead cost outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug fee expense cost advertising include promotional expense incur advertising expense million million million year end december respectively cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent marketable nonmarketable security marketable debt security determine appropriate classification marketable debt security time purchase reevaluate designation balance sheet date marketable debt security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale debt security exclude net income report accumulate comprehensive income loss aoci separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline marketable nonmarketable equity security investment equity security equity method investment record fair market value fair value readily determinable equity security readily determinable fair value record measurement alternative cost impairment adjust observable price change orderly transaction identical similar investment issuer certain investment equity security nonpublic company account equity method base ownership percentage factor indicate significant influence investee investment equity securities record prepay current asset long term asset consolidate balance sheet unrealize gain loss record income expense net regularly review security indicator impairment investment nonpublic company material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe japan date experience significant loss respect collection account receivable believe allowance doubtful account adequate december certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate wholesaler chargeback government program cash discount base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant inventory inventory record low cost net realizable value cost determine firstin firstout basis periodically review inventory identify obsolete slowmove excess unsaleable item obsolete excess unsaleable item observe alternate use inventory record inventory valuation reserve charge cost good sell consolidated statement income establishment inventory valuation reserve calculation reserve require judgment include consideration factor estimate future product demand product net selling price current future market condition potential product obsolescence future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate rd initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement short year useful life laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term acquisition account business combination acquisition method accounting require asset acquire include inprocess research development iprd project liability assume record fair value acquisition date consolidate balance sheet excess purchase price fair value net asset acquire record goodwill determination estimate fair value require significant estimate assumption result record adjustment fair value asset acquire liability assume measurement period year acquisition date correspond offset goodwill transaction cost associate business combination expense incur determine net asset acquire meet definition business combination acquisition method accounting transaction account acquisition asset business combination goodwill record goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelive amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event circumstance indicate fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment fact circumstance internally externally suggest carry value asset recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset carrying asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component aoci stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss immaterial year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrealize gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning aoci depend derivative designate hedge transaction type hedge transaction assess inception ongoing basis derivative hedging transaction effective offset change cash flow fair value hedge item determine forecast transaction probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize income expense net consolidated statement income income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation applicable tax law regulation record liability relate unrecognized tax benefit accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return adverse resolution uncertain tax position period material impact result operation period elect account tax global intangible lowtaxed income enact tax cut job act tax reform component tax expense period tax incur recently adopt accounting pronouncement financial accounting standard board fasb issue topic entity adopt topic option retrospective modify retrospective approach january adopt topic modify retrospective method apply contract complete january result report period begin january present topic prior period amount adjust continue report accordance historical accounting topic discuss product sale recognize control product transfer generally shipment delivery customer certain case correspond sale customer party certain product sale defer sellthrough cash basis method accounting fee fix determinable prior adoption topic recognize transfer control royalty revenue recognize period correspond sale corporate partner occur prior adoption topic royalty revenue generally recognize quarter follow quarter correspond sale corporate partner occur cumulative effect change consolidated balance sheet january adoption topic follow million adjustment topic december january prepay current asset longterm asset accrue liability longterm obligation retain earning impact consolidate financial statement result apply topic place topic material january fasb issue accounting standard update financial instrument overall recognition measurement financial asset financial liability asu asu change accounting equity investment financial liability fair value option presentation disclosure requirement financial instrument additionally asu clarifie guidance relate valuation allowance assessment recognize defer tax asset result unrealized loss availableforsale debt security january adopt standard modify retrospective approach standard require equity investment readily determinable fair value measure fair value change fair value recognize earning result adoption reclassify million unrealized net gain aoci retain earning january primarily consist million unrealized gain equity investment galapagos nv august fasb issue accounting standard update derivative hedge target improvement accounting hedging activity asu amendment asu closely align result hedge accounting risk management activity asu amend presentation disclosure requirement ease documentation effectiveness assessment requirement january early adopt standard prospective basis adoption asu long recognize hedge ineffectiveness consolidate statement income instead recognize entire change fair value hedge contract aoci adoption material impact consolidate financial statement primary impact adoption require disclosure change note derivative financial instrument additional information march fasb issue accounting standard update income taxis topic amendment sec paragraph pursuant sec staff accounting bulletin asu asu amend topic incorporate sec staff accounting bulletin sab issue december sab provide guidance accounting effect tax reform allow company record provisional amount measurement period extend year enactment date note income taxis additional information recently issue accounting pronouncement adopt february fasb issue accounting standard update lease topic topic amend number aspect lease accounting include require lessee recognize lease term great year rightofuse asset correspond liability measure present value lease payment july fasb issue supplemental adoption guidance clarification topic asu codification improvement topic lease asu lease topic target improvement guidance effective begin quarter modify retrospective transition approach require plan adopt standard effective date recording cumulative effect adjustment opening balance retain earning january base lease portfolio december anticipate recognition lease asset liability approximately million consolidated balance sheet adoption material impact consolidate statement income elect practical expedient transition reassess prior conclusion relate contract contain lease lease classification initial direct cost elect practical expedient lessee combine lease nonlease component asset class process finalize key system functionality update control procedure maintain accounting lease portfolio new guidance june fasb issue accounting standard update financial instrumentscredit loss measurement credit loss financial instrument asu asu require measurement recognition expect credit loss financial asset guidance effective begin quarter adopt modify retrospective approach certain exception early adoption permit begin quarter evaluate impact adoption standard consolidated financial statement november fasb issue accounting standard update collaborative arrangement topic clarify interaction topic topic asu asu clarifie certain transaction collaborative arrangement participant account revenue topic collaborative arrangement participant customer context unit account add unitofaccount guidance topic align guidance topic preclude entity present amount relate transaction collaborative arrangement participant customer revenue transaction directly relate thirdparty sale guidance effective begin quarter apply retrospectively january initially adopt topic early adoption permit evaluate impact adoption standard currently expect material impact revenue revenue disaggregation revenue follow table disaggregate product sale product geographic region disaggregate royalty contract revenue geographic region year end december information year end december adjusted accordance modify retrospective adoption topic continues report accordance historical accounting topic year end december year end december year end december million europe international total europe international total europe international total product sale atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza ambisome epclusa harvoni letairis ranexa vemlidy viread vosevi yescarta zydelig total product sale royalty contract revenue total revenue note include emtriva tybost represent gileads revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fix dose combination product commercialize janssen sciences ireland uc janssen include cayston hepsera sovaldi revenues recognize performance obligation satisfy prior period year end december revenue recognize performance obligation satisfy prior year relate royalty license intellectual property million change estimate variable consideration relate sale prior year result million decrease revenue year end december contract balances contract asset consist unbilled amount primarily arrangement license intellectual property predominant performance obligation total million million december january respectively contract liability material december january fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist primarily cash cash equivalent marketable debt security account receivable foreign currency exchange contract equity security account payable shortterm longterm debt cash cash equivalent marketable debt equity security foreign currency exchange contract report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidate balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value follow table summarize type asset liability measure fair value recur basis level fair value hierarchy million december december level level level total level level level total asset availableforsale debt security treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage assetbacke security marketable equity security money market fund equity security defer compensation plan foreign currency derivative contract total liability defer compensation plan foreign currency derivative contract total year end december change fair value marketable equity security result net unrealized gain million include income expense net consolidated statement income follow table summarize classification marketable equity security consolidate balance sheet million december december cash cash equivalent prepay current asset longterm asset total availableforsale debt security classify cash equivalent shortterm marketable security longterm marketable security consolidate balance sheet note availableforsale debt security additional information level input estimate fair value level instrument take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include incomebase marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent sp global rating moodys investors service inc fitch ratings inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency exchange rate london interbank offer rate libor swap rate input applicable observable commonly quote interval total estimate fair value shortterm longterm debt determine level input base quote market value approximately billion billion december respectively carry value billion billion december respectively level input december asset liability measure level input recur basis contingent consideration liability immaterial nonrecurre basis measure certain asset include intangible asset fair value carry value asset exceed fair value record impairment charge million write zero carry value kite program antibcma evaluate treatment multiple myeloma note intangible asset additional information policy recognize transfer level classification actual date event change circumstance cause transfer transfer level level level period present availableforsale debt security follow table summarize availableforsale debt security million december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value treasury security certificate deposit government agency security nonus government security corporate debt security residential mortgage assetbacke security total follow table summarize classification availableforsale debt security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security total follow table summarize availableforsale debt security contractual maturity million december amortize cost fair value year year year year year year total follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december treasury security government agency security nonus government security corporate debt security residential mortgage assetbacke security total december treasury security government agency security nonus government security corporate debt security residential mortgage assetbacked security total hold total position unrealize loss position december respectively base review security believe otherthantemporary impairment december intend sell security believe require sell security recovery amortize cost basis gross realize gain gross realize loss material year present derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency primarily euro order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability entity denominate non functional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity month execute hedge contract quarterly assess hedge effectiveness regression analysis prior january exclude time value effectiveness testing recognize change time value hedge income expense net consolidated statement income start january include time value effectiveness testing entire change value hedge contract record unrealized gain loss aoci stockholder equity consolidate balance sheet unrealize gain loss aoci reclassify product sale respective hedge transaction affect earning majority gain loss relate hedged forecast transaction report aoci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion billion december respectively derivative contract allow right offset asset liability present amount gross basis follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain loss recognize aoci gain loss reclassify aoci product sale gain loss recognize income expense net derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net consolidated statement income year present result discontinuance cash flow hedge december hold foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet million december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability acquisition kite pharma inc october acquisition date complete tender offer outstanding common stock kite pharma inc kite share cash result kite whollyowne subsidiary acquisition kite help establish foundation improve treatment hematological malignancy solid tumor consideration transfer acquisition million consist million cash outstanding kite common stockholder million cash payment vested equity award holder million warrant holder million represent portion replace stockbase award attributable precombination period addition million exclude consideration transfer represent portion replace stock base award attributable post combination period expect recognize acquisition kite account business combination acquisition method accounting method require thing asset acquire liability assume recognize fair value acquisition date determination estimate fair value require significant estimate assumption record million reduction goodwill primarily revision defer income taxis result finalization kite preacquisition federal income tax return fair value estimate asset acquire liability assume complete follow table summarize acquisition date fair value asset acquire liability assume consideration transfer millions cash cash equivalent identifiable intangible asset indefinitelive intangible asset iprd outlicense acquire deferred income taxis asset acquire liability assume net total identifiable net asset goodwill total consideration transfer identifiable intangible asset acquire intangible asset primarily related iprd axicabtagene ciloleucel kite ktex ktec evaluate treatment adult pediatric acute lymphoblastic leukemia estimate aggregate fair value million acquisition date intangible asset relate iprd project consider indefinitelive asset completion abandonment associate rd effort october fda approval yescarta treatment adult patient relapse refractory dlbcl line systemic therapy million purchase iprd reclassify finitelived intangible asset amortize estimate useful life year straight line method record impairment charge million write zero estimate fair value kite program note intangible asset additional information additionally acquire outlicense arrangement daiichi sankyo company limit estimate fair value million acquisition date definitelive intangible asset amortize estimate useful life year straightline basis fair value determine estimate probabilityweighte net cash flow attributable outlicense discount present value discount rate represent estimate rate market participant use value intangible asset goodwill million goodwill represent excess consideration transfer fair value asset acquire liability assume represent future economic benefit arise asset acquire individually identify separately recognize goodwill deductible income tax purpose cell design labs inc december acquire issue outstanding stock cell design labs inc privately hold company cell design lab addition approximately share cell design lab obtain acquisition kite acquisition gain new technology platform enhance research development effort cellular therapy cash consideration total million net acquire cash additionally shareholder cell design lab eligible receive contingent development regulatory milestonebase payment million equity interest cell design lab carry value million transaction account asset acquisition result million expense acquire iprd research development expense consolidate statement income nimbus apollo inc acquire nimbus apollo inc privately hold company acetylcoa carboxylase inhibitor program evaluate potential treatment nonalcoholic steatohepatitis hepatocellular carcinoma disease consideration include payment million contingent development regulatory milestonebase payment million transaction account asset acquisition result payment million expense acquire iprd research development expense consolidate statement income base achievement certain clinical development milestone record million expense research development expense consolidate statement income inventory inventory summarize follow million december raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december year end december record inventory reserve million million relate excess raw material primarily sustained decrease demand harvoni inventory reserve record year end december material property plant equipment property plant equipment summarize follow million december land land improvement building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization total office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million million december respectively capitalize interest construction inprogress include property plant equipment interest capitalize material intangible asset follow table summarize intangible asset net million december december gross foreign currency gross carry accumulate translation net carry carry accumulate net carrying amortization adjustment amortization finitelive asset intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total finitelive asset indefinitelive asset iprd total intangible asset amortization expense relate finitelived intangible asset include cost good sell consolidated statement income total billion million million year end december respectively enter agreement japan tobacco inc japan tobacco acquire right market distribute certain product hiv portfolio japan connection agreement record intangible asset million reflect estimate fair value marketingrelate right acquire japan tobacco intangible asset amortize year begin january amortization expense classify selling expense record sell general administrative expense consolidate statement income note collaborative arrangement additional information conclude kite program justify effort base totality clinical datum gather discontinue program result carry value iprd relate kite program write zero record impairment charge million research development expense consolidate statement income iprd impairment charge record million iprd impairment charge record research development expense consolidate statement income enter collaboration agreement gadeta bv gadeta develop gamma delta cell receptor therapie cancer gadeta vie consolidate consolidation recognize million indefinitelive intangible asset relate iprd note collaborative arrangement additional information december estimate future amortization expense associate finitelive intangible asset follow millions fiscal year total financial information accrue liability component accrue liability summarize follow million december compensation employee benefit accrue payment marketingrelate right acquire japan tobacco income taxis payable accrue expense total collaborative arrangement enter collaborative arrangement party development commercialization certain product product candidate arrangement involve party active participant operating activity collaboration expose significant risk reward depend commercial success activity arrangement include nonrefundable upfront payment payment option acquire certain right contingent obligation potential development regulatory milestone payment andor salesbase milestone payment royalty payment revenue profitshare arrangement costshare arrangement equity investment combination term janssen compleraeviplera odefsey enter license collaboration agreement janssen sciences ireland uc janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union agreement amend expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide odefsey amend agreement janssen grant exclusive license compleraeviplera odefsey worldwide retain right distribute combination product certain country outside united states party restrict combine drug drug product similar component compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country sell party financial provision amendment sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue major market sale product include product sale janssen share revenue include cost good sell consolidated statement income cost good sell relate janssen share million million million year end december respectively termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term terminate agreement cause respect country sell product case janssen right sell party country product launch market few year symtuza amend license collaboration agreement janssen develop commercialize fixeddose combination janssen darunavir cobicistat emtricitabine tenofovir alafenamide combination approve united states european union july september respectively sell brand symtuza term amendment grant janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property relate cobicistat emtricitabine tenofovir alafenamide gilead compound exclusive supplier gilead compound party restrict combine drug drug product similar component symtuza janssen set price symtuza party share revenue base ratio net selling price party component subject certain restriction adjustment intellectual property license supply obligation relate gilead compound account single performance obligation license deem predominant item revenue share relate recognize share symtuza revenue period correspond sale symtuza janssen occur record share symtuza revenue product sale consolidate statement income primarily supply gilead compound janssen symtuza note revenue revenue recognize period present termination agreement product country basis depend circumstance include withdrawal product market material breach party expiry revenue share payment term janssen terminate agreement cause countrybycountry basis case gilead right sell party countryie product launch market few year janssen terminate entire agreement cause japan tobacco japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right pay royalty base product sale japan agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort pay royalty japan tobacco base product sale japan tobacco market distribute certain product hiv portfolio japan pay royalty base product sale receive approval stribild genvoya elvitegravircontaine product respectively sale product include product sale royalty japan tobacco base product sale include cost good sell royalty japan tobacco base product sale japan include royalty contract revenue consolidate statement income royalty expense recognize million million million year end december respectively royalty income recognize material period present effective december enter agreement japan tobacco acquire right market distribute certain product hiv portfolio japan expand right develop commercialize elvitegravir include japan responsible marketing product january term agreement obligate pay japan tobacco million cash million pay upfront payment remain million reflect accrue liability consolidate balance sheet december recognize intangible asset million reflect estimate fair value marketingrelate right acquire japan tobacco remain million record prepay current asset consolidate balance sheet intangible asset amortize year represent period majority benefit expect derive applicable product hiv portfolio amortization expense classify selling expense record sell general administrative expense consolidate statement income termination agreement product country basis depend circumstance include material breach party expiry royalty payment term terminate entire agreement cause galapagos close license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor evaluate inflammatory disease indication closing license collaboration agreement upfront license fee payment million million equity investment galapago subscribe new share price share include issuance premium result receive million new share galapago represent outstanding share capital closing license collaboration agreement license fee payment million issuance premium equity investment million record research development expense consolidate statement income equity investment net issuance premium record prepay current asset consolidate balance sheet december fair value investment million galapago eligible receive development regulatory milestonebase payment million salesbase milestone payment million plus tiere royalty global net sale range exception certain copromotion territory profit share equally year end december milestone payment galapago material year end december record million expense base achievement certain clinical development milestone research development expense consolidate statement income term agreement exclusive worldwide royaltybearing sublicensable license filgotinib product contain filgotinib primarily responsible development seek regulatory approval relate filgotinib responsible galapago responsible development cost incur year present payment galapagos development cost material responsible manufacturing commercialization activity galapago exercise option copromote filgotinib uk germany france italy spain netherlands belgium luxembourg territory galapagos share profit equally termination agreement country basis depend circumstance include expiration royalty term copromotion territory sale generic product material breach party terminate entire agreement cause follow certain period gadeta july enter collaboration arrangement gadeta privatelyheld company base utrecht netherlands develop gamma delta cell receptor therapie cancer financial term provide rd funding collaboration gadeta eligible receive future payment achievement certain regulatory milestone addition upfront purchase equity gadeta gadeta shareholder acquire additional equity gadeta achievement certain rd milestone exclusive option acquire remain equity gadeta million adjust closing cash transaction expense close indebtedness option exercisable discretion gadeta vie primary beneficiary power direct activity gadeta significantly impact economic performance result financial term describe initial consolidation gadeta record asset million primarily intangible asset relate iprd million noncontrolling interest consolidate balance sheet gadeta meet definition business define asc business combination result goodwill recognize bristolmyers squibb company north america enter collaboration arrangement bristolmyer squibb company bms develop commercialize single tablet regimen contain truvada bmss sustiva efavirenz united states canada combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company consolidate december terminate bmss participation collaboration follow launch generic version sustiva sole owner joint venture bms permit commercialize atripla united states canada entitle receive certain fee base net sale atripla decline annual scale continue purchase efavirenz bms cost plus markup need continue manufacturing atripla united states canada markets year end december record million fee expense cost good sell consolidated statement income europe gilead sciences ireland uc whollyowne subsidiary bms enter collaboration agreement set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bmss estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bmss estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain fee base net sale threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early collaboration arrangement individually significant enter collaboration arrangement result cash payment million million record collaboration expense research development expense consolidate statement income remain amount record current longterm asset consolidate balance sheet consider collaboration arrangement individually material material initial cash payment relate individually insignificant collaboration arrangement financial term arrangement require payment achievement developmental regulatory commercial milestone significant addition require pay significant royalty future sale product relate arrangement commercialize payment amount contingent occurrence future event high degree uncertainty occurrence future milestone payment royalty reflect consolidated statement income correspond event probable debt credit facility follow table summarize carry borrowing financing arrangement million december type borrowing issue date date interest rate senior unsecured september september senior unsecured september september month libor term loan october october variable senior unsecured september march month libor senior unsecured march april senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september term loan october october variable senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september term loan october october variable senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net current portion total longterm debt net senior unsecured note connection acquisition kite issue billion aggregate principal senior unsecured note register offering consist million principal float rate note september million principal float rate note march million principal float rate note september collectively float rate note billion principal senior note september fix rate note collectively float rate note note term summarize table repay maturity million principal balance relate float rate note collectively refer note senior unsecured note issue september note september notes march november notes march december note senior note repay maturity billion principal balance relate note senior note float rate note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior note mature feature exercisable option redeem note par month immediately precede maturity case accrue unpaid interest require redeem date redemption option redeem series float rate note prior maturity date event occurrence change control downgrade rate senior note investment grade moodys investors service inc sp global rating holder require purchase portion note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase require comply certain covenant senior note december violation covenant interest expense senior note relate contractual coupon rate amortization debt discount issuance cost billion billion million respectively term loan facility september enter billion aggregate principal term loan facility credit agreement consist billion principal day senior unsecured term loan facility billion principal threeyear senior unsecured term loan facility billion principal fiveyear senior unsecured term loan facility collectively term loan facility october draw billion principal term loan facility proceed finance acquisition kite billion repay remain billion repay term loan facility credit agreement terminate credit facility enter billion fiveyear revolve credit facility agreement mature fiveyear revolve credit agreement revolve credit facility work capital requirement general corporate purpose include limitation acquisition december amount outstanding fiveyear revolve credit agreement fiveyear revolve credit agreement contain customary representation warranty affirmative negative covenant event default december violation covenant loan fiveyear revolve credit agreement bear interest eurodollar rate plus applicable percentage ii base rate plus applicable percentage define fiveyear revolve credit agreement terminate reduce commitment prepay loan fiveyear revolve credit agreement time premium penalty contractual maturity finance obligation december aggregate future principal maturity finance obligation year base contractual date follow millions contractual maturity commitment contingency lease arrangement lease facility equipment relate primarily administrative rd sale marketing activity longterm noncancelable operating lease united states international market lease expire date lease contain option renew lease expense operating lease million million million respectively aggregate undiscounte noncancelable future minimum rental payment operating lease follow million total legal proceeding party legal action significant describe recognize accrual action extent conclude loss probable reasonably estimable accrue good estimate loss range estimate range well accrue minimum range determine loss reasonably possible loss range loss estimate disclose possible loss note possible determine outcome matter reasonably estimate maximum potential exposure range possible loss recognize accrual action describe consolidated balance sheet december believe loss probable litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hepatitis c virus hcv december receive approval food drug administration fda sofosbuvir know commercially sovaldi sofosbuvir include market hcv product receive number claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss aware patent patent application own party future allege party cover use hcv product party obtain valid enforceable patent successfully prove infringement patent hcv product require pay significant monetary damage predict ultimate outcome intellectual property claim relate hcv product spend continue spend significant resource defend claim litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent patent idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos patent patent court transfer massachusetts litigation district court district delaware prior trial idenix commit covenant sue respect claim arise patent relate sofosbuvir withdraw patent trial jury trial hold patent jury find willfully infringe assert claim patent award idenix billion past damage judge invalidated idenixs patent vacate jurys award billion past damage idenix appeal decision court appeal federal circuit cafc briefing complete believe delaware court decision correctly find matter law patent invalid remain confident merit case appeal believe possibility material adverse outcome matter remote european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold epo rule favor revoke patent idenix appeal idenix initiate infringement proceeding germany france allege commercialization sovaldi infringe german french counterpart patent german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo idenix appeal decision german court staying proceeding idenixs request french proceeding stay litigation merck co inc merck merck contact request pay royalty sale sofosbuvir obtain license patent patent patent patent coown ionis pharmaceuticals inc patent cover compound include relate sofosbuvir file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe initially jury determine establish merck patent invalid award merck million damage court rule favor defense unclean hand determine merck recover damage patent cafc affirm court decision unclean hand supreme court deny merck petition review merit portion case final litigation university minnesota university minnesota university obtain patent patent purport broadly cover nucleosides antiviral anticancer activity university file lawsuit district court district minnesota allege commercialization sofosbuvircontaine product infringe patent believe patent invalid infringe continue commercialization sofosbuvir court grant motion transfer case california file petition inter part review uspto patent trial appeal board ptab allege assert claim invalid anticipation obviousness district court stay litigation ptab rule petition inter part review litigation relate axicabtagene ciloleucel acquire kite whollyowne subsidiary acquisition acquire axicabtagene ciloleucel chimeric antigen receptor car cell therapy receive approval fda axicabtagene ciloleucel know commercially yescarta patent patent application claim axicabtagene ciloleucel chimeric dna segment party obtain right patent allegedly prevent attempt prevent commercialize axicabtagene ciloleucel require obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively license patent patent issue sloan kettering cancer center september juno sloan kettering cancer center file lawsuit kite district court central district california allege commercialization axicabtagene ciloleucel infringe patent october follow fda approval yescarta juno file second complaint allege axicabtagene ciloleucel infringe patent juno subsequently move dismiss september complaint maintain october complaint court set trial date december lawsuit predict ultimate outcome intellectual property claim relate axicabtagene ciloleucel junos patent uphold valid juno successfully prove infringement patent axicabtagene ciloleucel require pay significant monetary damage prevent sell yescarta able obtain license patent license available commercially reasonable term litigation relate bictegravir viiv healthcare company viiv file lawsuit district court delaware allege commercialization bictegravir know commercially biktarvy infringe viiv patent patent issue shionogi co ltd glaxosmithkline llc patent compound patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claim invalid patent trademark office uspto grant patent cover bictegravir court set trial date september lawsuit viiv file lawsuit federal court canada allege activity relate bictegravir product infringe viiv canadian patent patent issue shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claim patent extent viivs patent claim interpret cover bictegravir believe claim invalid predict ultimate outcome intellectual property claim relate bictegravir viivs patent uphold valid viiv successfully prove infringement patent bictegravir require pay significant monetary damage litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation seek approval generic version product nce status generic company submit anda fda year brand product approval current legal proceeding significance generic manufacturer include hiv product receive notice strides pharma inc stride submit anda fda request permission manufacture market generic version truvada notice stride allege patent associate emtricitabine patent associate emtricitabine tenofovir disoproxil fumarate fixeddose combination invalid unenforceable andor infringe strides manufacture use sale generic version truvada response file lawsuit stride district court district new jersey infringement patent reach agreement stride resolve lawsuit dismiss settlement agreement file federal trade commission department justice require law receive notice zydus pharmaceuticals usa inc zydus submit anda fda request permission manufacture market generic version truvada dosage strength notice zydus allege patent associate emtricitabine patent associate emtricitabine tenofovir disoproxil fumarate fixeddose combination invalid unenforceable andor infringe zydus manufacture use sale generic version truvada dosage strength response file lawsuit zydus district court district new jersey infringement patent receive notice mylan pharmaceuticals inc mylan submit anda fda request permission manufacture market generic version stribild notice mylan allege patent own japan tobacco inc jt associate elvitegravir invalid unenforceable andor infringe mylan manufacture use sale generic version stribild jt file lawsuit mylan district court northern district west virginia infringement patent hcv product receive notice natco pharma limited natco teva pharmaceuticals teva submit anda fda request permission manufacture market generic version sovaldi tevas notice allege patent associate sofosbuvir invalid unenforceable andor infringe tevas manufacture use sale generic version sovaldi response file lawsuit teva district court district new jersey district court district delaware infringement patent natcos notice allege patent associate sofosbuvir invalid unenforceable andor infringe natcos manufacture use sale generic version sovaldi natco challenge patent list orange book sovaldi file lawsuit natco district court district new jersey district court district delaware infringement patent reach agreement teva resolve lawsuit dismiss settlement agreement file federal trade commission department justice require law european patent claim party file opposition epo request revocation grant european patent cover sofosbuvir expire epo uphold validity certain claim sofosbuvir patent appeal decision seek restore original claim original oppose party appeal request revocation appeal process year party file opposition epo request revocation grant european patent relate sofosbuvir expire epo conduct oral hearing opposition uphold claim original oppose party appeal request revocation appeal process year party file opposition epo request revocation grant european patent cover taf expire epo upheld validity claim taf patent party appeal decision appeal process year party file opposition epo request revocation grant european patent relate taf hemifumarate expire respond opposition hear hold february patent uphold hearing oppose party choose appeal decision year conclude party file opposition epo request revocation grant european patent cover cobicistat expire epo upheld validity claim cobicistat patent original oppose party appeal decision appeal process year confident strength patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir taf cobicistat european union substantially shorten eliminate entirely patent revoke european patent grant covering compound exclusivity base entirely regulatory exclusivity grant european medicine agency sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose patent protection sofosbuvir prior revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline government investigation relate litigation receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry department justice inform follow investigation decline intervene false claim act lawsuit file employee employee serve amend complaint district court northern district california issue order grant entirety prejudice motion dismiss amend complaint plaintiff file second amend complaint district court issue order grant motion dismiss second amend complaint plaintiff file notice appeal court appeal ninth circuit ninth circuit grant motion stay case pende appeal supreme court file petition writ certiorari supreme court solicitor general submit brief united states supreme court state intention file motion dismiss federal false claim act january supreme court deny petition case remand district court receive subpoena attorney office district massachusetts request document relate support c organization provide financial assistance patient document concern provision financial assistance patient hcv product cooperate inquiry receive subpoena attorney office district massachusetts request document relate copay coupon program medicaid price report methodology cooperate inquiry receive voluntary request information attorney office eastern district pennsylvania request information relate reimbursement support offering clinical education program interaction specialty pharmacy sovaldi harvoni receive voluntary request information relate speaker program advisory board hcv hepatitis b virus hbv product cooperate voluntary request receive subpoena california department insurance alameda county district attorney office request document relate marketing activity reimbursement support offering clinical education program interaction specialty pharmacy harvoni sovaldi cooperate inquiry receive subpoena department health human service request document relate frontlines communities united states focus program cooperate inquiry february government inform decline intervene false claim act qui tam lawsuit relate inquiry receive subpoena attorney office southern district new york request document relate promotional speaker program hiv cooperate inquiry product liability plaintiff file purport mass action district court northern district california holley action plaintiff allege suffer kidney andor bone injury result viread truvada atripla complera andor stribild allege altered design medication replace active ingredient tenofovir disoproxil fumarate tdf allegedly superior ingredient tenofovir alafenamide fumarate andor reduce dose tdf stribild fail adequately warn plaintiff physicians kidney bone risk viread truvada atripla complera stribild need monitor patient risk base allegation plaintiff assert claim product liability negligence fraud breach warranty violation state consumer protection law plaintiff seek compensatory statutory punitive damage restitution federal lawsuit pende district court central district california dechow action district court middle district louisiana hills action district court western district louisiana pierot action district court northern district california dowdy action base allegation similar raise holley action addition pende federal action lawsuit base plaintiff allegation similar raise holley action pende california state court lujano martinez grim action file motion dismiss holley dowdy hill pierot lujano action motion dismiss lujano action grant plaintiff strict product liability claim deny remain claim motion dismiss remain pende plan file motion dismiss dechow martinez grim action intend vigorously defend action believe case merit predict ultimate outcome plaintiff successful claim require pay significant monetary damage matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately million million million million million amount relate active pharmaceutical ingredient represent minimum purchase commitment actual payment purchase relate active pharmaceutical ingredient certain inventory relate item billion billion billion stockholder equity stock repurchase program quarter board director authorize billion stock repurchase program program repurchase open market privately negotiate transaction program commence april billion stock repurchase program authorize board director january program complete december remain authorize repurchase program billion follow table summarize stock repurchase abovedescribe program millions share datum year end december share repurchase retire average price share note repurchase program include million share repurchase billion program million share repurchase billion program addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation immaterial exclude table use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate apic base estimate average sale price issue share excess amount charge retain earning follow table summarizes reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning dividend follow table summarize cash dividend declare common stock million share datum dividend share dividend share quarter second quarter quarter fourth quarter total restrict stock performancebase stock unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march future dividend subject declaration board director prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income loss follow table summarize change aoci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss translation security cash flow hedge total balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december reclassification retain earning result adoption new accounting standard balance january net unrealize gain loss reclassification net income net current period comprehensive income loss balance december amount reclassify net income gain loss cash flow hedge record product sale consolidate statement income note derivative financial instrument additional information amount reclassify net income gain loss availableforsale debt security record income expense net consolidated statement income employee benefit provide share base compensation form type equitybase award include restrict stock unit rsus performancebase restrict stock unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan amend plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage aggregate average remain intrinsic share exercise price contractual term value thousand dollar year million outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise million million million weightedaverage grant date fair value stock option grant share share share weightedaverage grant date fair value stock option grant high replacement award grant connection acquisition kite cell design labs december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performancebase restrict stock unit plan grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information psus weight average grant date fair value share share thousand dollar outstanding december grant vest forfeited outstanding december note weightedaverage grantdate fair value share exclude share relate grant currently grant date performance objective define weightedaverage grant date fair value psus grant share share share total grant date fair value vest psus million million million total fair value respective vest date million million million recognize stockbased compensation expense million million million related psus december million unrecognized compensation cost relate psus expect recognize estimate weightedaverage period year restrict stock unit grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest rsus generally vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information weight average grant date fair value share share thousand dollar outstanding december grant vest forfeited outstanding december weightedaverage grant date fair value rsus grant share share share total grant date fair value vest rsus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date prior espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period begin quarter lookback feature espp offering period sixmonth espp purchase settle common stock espps previously authorize available pool share million share issue espp million total million share common stock authorize issuance espp million share available issuance espp december stockbase compensation follow table summarize total stockbased compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach reduce estimate forfeiture estimate forfeiture base historical experience valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potentially dilutive share common stock result assume exercise outstanding stock option equivalent assume conversion outstanding convertible note assume exercise warrant relate outstanding convertible note determine treasury stock method convertible note associate warrant settled exclude stock option equivalent approximately million million million weightedaverage share common stock outstanding respectively computation dilute net income share attributable gilead common stockholder effect antidilutive follow table show calculation basic diluted net income share attributable gilead common stockholder million share amount year end december net income attributable gilead share share calculation basic effect dilutive security stock option equivalent conversion spread relate convertible note warrant relate convertible note share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need result operation report consolidated basis consistent internal management reporting review chief operating decision maker chief executive officer interim chief executive officer note revenue summary disaggregate revenue product geographic region revenue major customer follow table summarize revenue customer individually account total revenue percentage total revenue year end december amerisourcebergen corp cardinal health inc mckesson corp longlived assets net book value property plant equipment office computer equipment united states billion december billion december billion december corresponding international location million december million december million december individual international location account percent total balance income taxis income provision income taxis consist follow millions year end december domestic foreign total income provision income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis provision income taxis include million defer tax charge previously acquire intangible asset result transfer asset wholly own subsidiary provision income taxis include billion provisional charge income tax expense relate tax reform enact december december tax reform sign law make significant change internal revenue code amend change include limited corporate tax rate decrease effective tax year begin december repatriation tax deem repatriate earning foreign subsidiary implementation modify territorial tax system effect subject earning foreign subsidiary taxation global intangible lowtaxed income gilti result record provisional charge income tax expense billion december include provisional million deferred tax benefit relate remeasurement certain defer tax asset liabilitie billion provisional charge relate transition tax mandatory deem repatriation accumulate foreign earning accounting income tax effect tax reform complete accordance sab result record million net tax charge income tax provision primarily relate deferred tax revaluation partially offset refinement provisional estimate transition tax december accrue federal liability transition tax billion payable year period december accrue federal liability transition tax billion include longterm income taxis payable consolidated balance sheet decrease billion primarily billion payment million refinement provisional estimate year end december repatriate billion cash cash equivalent marketable security parent company headquarter united states prior enactment tax reform earning consider indefinitely reinveste taxis provide taxis provide earning accrual transition tax additionally complete evaluation accounting policy election require regard tax gilti fasb allow company adopt policy election account tax gilti method account tax gilti component tax expense period tax incur period cost method ii account tax gilti company measurement defer taxis defer method elect account tax gilti period cost method reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit tax foreign earning defer tax charge acquire intangible transition tax defer tax revaluation settlement tax examination effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible total defer tax liability net defer tax asset liability valuation allowance million million december respectively increase valuation allowance primarily related certain kite tax attribute certain foreign jurisdiction sufficient history profit realize benefit loss morelikelythannot basis december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforward approximately million start expire utilize addition state net operating loss tax credit carryforward approximately billion million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return unite states foreign jurisdiction federal income tax purpose statute limitation open onwards onwards california income tax purpose certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total unrecognized tax benefit billion billion december recognize reduce effective tax rate period recognition include interest penalty relate unrecognized tax benefit provision income taxis consolidate statement income accrue interest penalty relate unrecognized tax benefit million million december respectively december believe reasonably possible unrecognized tax benefit decrease approximately million month potential settlement tax authority follow rollforward total gross unrecognized tax benefit millions december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period select quarterly financial information unaudite follow amount million share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute total revenue gross profit product sale net income loss net income loss attributable gilead net income loss share attributable gilead common stockholder basic net income loss share attributable gilead common stockholder diluted note amount fourth quarter include million million impairment noncash tax charge relate intangible asset acquire kite pharma inc respectively inventory reserve million excess raw material primarily sustained decrease demand harvoni note inventory note intangible asset note income taxis note consolidated financial statement include item annual report additional detail amount fourth quarter include unfavorable impact basic share diluted share factor note december record billion net charge basic share diluted share relate enactment tax cut job act note income taxis note consolidated financial statement include item annual report additional detail gilead sciences inc schedule ii valuation qualifying account million balance begin additionscharged balance end period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset note allowance doubtful account cash discount chargeback item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include interim chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify security exchange commission rule form information accumulate communicate company management include interim chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation interim chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include interim chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include item annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include interim chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm shareholder board director gilead sciences inc opinion internal control financial reporting audit gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criterion opinion gilead sciences inc company maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states pcaob consolidate balance sheet company december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december relate note financial statement schedule list index item report date february express unqualified opinion thereon basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ernst young llp san jose california february item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading gilead board director nominees board structure executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance intend disclose future amendment certain provision code ethic waivers code ethic grant executive officer director website business day follow date amendment waiver item executive compensation information require item incorporate reference section proxy statement heading executive compensation committee board director compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference item annual report head equity compensation plan information section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading gilead board director board process item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item